APPLIED GENETIC TECHNOLOGIES CORF
Form 8-K
September 10, 2018

**UNITED STATES** 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT** 

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 10, 2018

#### APPLIED GENETIC TECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

Delaware 001-36370 59-3553710 (State or Other Jurisdiction (Commission File Number) (IRS Employer

of Incorporation) Identification No.)

14193 NW 119th Terrace

Suite 10

Alachua, Florida, 32165 (Address of principal executive offices) (Zip Code)

(386) 462-2204

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

#### Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02	2 Results of Operations and Financial Condition.
Financia	ember 10, 2018, Applied Genetic Technologies Corporation issued a press release entitled "AGTC Announces I Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2018." The earnings f furnished herewith as Exhibit 99.1.
Item 9.0	1 Financial Statements and Exhibits.
(d) Exhibits.	
Exhibit	
Number	Description
99.1*	Press Release dated September 10, 2018, entitled "AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2018"
*Filed h	erewith.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

APPLIED GENETIC TECHNOLOGIES

**CORPORATION** 

By: s/ William Sullivan William A. Sullivan Chief Financial Officer

Date: September 10, 2018

2